Head-to-head evidence
EDP167 vs HRS-7249
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
EDP167
Developed by Eddingpharm (Zhuhai) Co., Ltd.
NCT07412080 · Phase 1 · completed
Participants were randomized to active drug or placebo with full blinding maintained, but the primary endpoint is safety and tolerability rather than a lipid or cardiovascular outcome, and results are not yet posted, so its eventual finding is unknown.
Next expected readout: November 2027 · NCT07799129 (registry estimate)
HRS-7249
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06541457 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled study, which is a sound design, but its primary measure is adverse-event safety rather than a lipid or cardiovascular efficacy outcome, and no results have been posted yet.
Next expected readout: June 2027 · NCT07308392 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: EDP167's landscape · HRS-7249's landscape